IAM Life Sciences: Key issues for senior life sciences executives 2019

WTR image

The key IP issues that entities operating in the pharmaceutical and biotechnology industries may confront as they develop and roll out their business strategies.

Articles

Inter partes review in the life sciences industry

Williams & Connolly LLP
Inter partes review is a pathway established by the America Invents Act to permit challenges to patents before the United States Patent and Trademark Office’s Patent Trial and Appeal Board.

Patent-eligible subject matter – the path to clarity and consistency requires legislative action

McAndrews
In the United States, the statutory requirements that determine whether an invention is patentable are codified in Chapter 35 of the United States Code (35 USC Sections 101, 102, 103 and 112).

The next generation of the US pharmaceutical industry

Buchanan Ingersoll & Rooney
The pharmaceutical industry in the United States is in a constant state of evolution, not only with regard to technological innovation, but also in terms of patent and regulatory strategies covering those products in development and on the market.

New chemical and pharmaceutical guidelines – a year on: what has changed?

Montaury Pimenta, Machado & Vieira de Mello
In January 2018 the Brazilian Patent and Trademark Office published completely new Guidelines for Examination of Patent Applications in the Chemistry Field.

Regulating cannabis use in Mexico – current legal framework

OLIVARES
Mexico’s current legislation regarding cannabis use is the result of several legal actions. More than five years ago, the first legal actions regarding the prohibition of cannabis use were filed by the authorities, pushing towards a specific legal framework.

Pepper plants lead to hot decisions and patentable subject matter

NLO
The Boards of Appeal recently decided that Rule 28(2) of the European Patent Convention (EPC) is in conflict with Article 53(b) of the EPC and that the article prevails over the rule under Article 164(2) of the EPC.

Clinical trial disclosures – an obstacle to patentability in Europe

COHAUSZ & FLORACK
Innovative pharmaceutical companies are faced with a dilemma when seeking patent protection at the European Patent Office for novel medical use or compound claims.

Patent practice: recent developments in life sciences in China

Liu Shen & Associates
Inventiveness has become an increasingly tough issue for patent practitioners in the chemical and biological fields in China. More and more weight is being given to the experimental data described in the original specification.

IP issues for life sciences companies in India

LexOrbis
The life sciences have expanded in all fields of technology, leading to the creation of one of the most complex systems of our time. The discipline of life sciences is no longer a standalone subject; it is an ever-evolving dynamic domain rapidly expanding and merging with other subjects.

IP strategy – it’s alive!

BRANN AB
IP strategy is a living creature – formulating a strategy at one point in time is all very well, but the market and competition will not remain idle. Players that did not exist when an IP strategy was first formulated may suddenly appear and the new market will need to develop to keep pace.

Pharmaceutical inventions and patent term extension procedure

Gorodissky & Partners
Once the Patent Law entered into effect in 1991, it became possible in Russia to get a national patent directed at pharmaceutical inventions. When the Eurasian Patent Convention entered into effect in 1995, it became possible to get a Eurasian patent on the same pharmaceutical inventions.